Austar Lifesciences (HKSE:06118) ROCE % : 4.28% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Austar Lifesciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Austar Lifesciences's annualized ROCE % for the quarter that ended in Dec. 2024 was 4.28%.

Austar Lifesciences ROCE % Historical Data

The historical data trend for Austar Lifesciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Austar Lifesciences ROCE % Chart

Austar Lifesciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

8.20

44.23

12.75

-2.01

4.02

Austar Lifesciences Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial															15.20	-12.57	8.82	3.80	4.28

Austar Lifesciences ROCE % Calculation

Austar Lifesciences's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	40.77	/	( ( (2361.438 - 1288.129)	+	(2224.639 - 1269.127) )	/ 2 )
	=	40.77	/	( (1073.309	+	955.512)	/ 2 )
	=	40.77	/	1014.4105
	=	4.02 %

Austar Lifesciences's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	42.284	/	( ( (2300.38 - 1278.531)	+	(2224.639 - 1269.127) )	/ 2 )
	=	42.284	/	( ( 1021.849	+	955.512 )	/ 2 )
	=	42.284	/	988.6805
	=	4.28 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

Austar Lifesciences (HKSE:06118) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Austar Lifesciences ROCE % Related Terms

Thank you for viewing the detailed overview of Austar Lifesciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Austar Lifesciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Austar Lifesciences Ltd (HKSE:06118) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

AULSF:USA

Address

No. 1018, Changning Road, Rooms 2010-2013, 20th Floor, Changning District, Shanghai, CHN

Website

https://www.austar.com.hk

Austar Lifesciences Ltd is a China-based company engaged in providing engineering solutions to pharmaceutical manufacturers and research institutes. The business activity of the group is operated through Liquid and Bioprocess Systems; Clean Room and Automation Control and Monitoring Systems; Powder and Solid Systems; Good Manufacturing Practice (GMP) Compliance Services; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment segments. It derives the majority of revenue from the Liquid and Bioprocess System segment which is involved in providing solutions in pharmaceutical and water systems to treat water. The geographical business presence of the firm is seen across China and in other countries.

Executives

True Worth Global Limited	2101 Beneficial owner
Cheung Chau Ping	2202 Interest of your spouse
Ho Kin Hung	2201 Interest of corporation controlled by you

Austar Lifesciences Headlines

No Headlines